RemeGen Co Stock

RemeGen Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co (9995.HK) as of Sep 10, 2026 is 377.52. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -21.41 — a change of -1,862.89% (higher).

EV/OCF

377.52

YoY

-1,862.89%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co is 2026 377.52 . EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co was 2025 -21.41 . It decreases by -1,862.89% higher compared to the previous year.

The RemeGen Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-184.63 CNY
Jan 1, 2019
-83.68 CNY
Jan 1, 2020
-31.88 CNY
Jan 1, 2021
83.34 CNY
Jan 1, 2022
-17.27 CNY
Jan 1, 2023
-16.00 CNY
Jan 1, 2024
-21.41 CNY
Jan 1, 2025
377.52 CNY
The RemeGen Co EV/OCF history
YEAREV/OCFYoY
377.52-1,862.89%
-21.41+33.81%
-16.00-7.31%
-17.27-120.72%
83.34-361.44%
-31.88-61.90%
-83.68-54.68%
-184.63
Access this data via the Eulerpool API

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co is 377.52 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of RemeGen Co changed from -21.41 to 377.52, representing a -1,862.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — RemeGen Co

All Key Metrics — RemeGen Co